Medication Summary

Medications to treat respiratory syncytial virus (RSV) infection include the antiviral drug ribavirin, which can be used in severe high-risk cases, and bronchodilators. The efficacy of bronchodilators or racemic epinephrine in treating RSV disease remains unproved. If these agents are given, attempts to measure response to therapy should be documented. If these treatments have no demonstrable benefit, they should be discontinued. Palivizumab may be given for prophylaxis.

A study evaluated the effectiveness of current regimens for palivizumab injections across different cities in order to design an optimized regimen. The study found that a 5-injection regimen using city-specific initiation dates would reduce the risk of RSV hospitalization by a median of 6.8%.^{[31, 32]}A study by Lavoie et al found that abbreviated three-and four dose regimens had comparable outcomes to infants treated with the five-dose regimen.^[33]

Class Summary

Antiviral therapy for severe RSV disease may be indicated in high-risk patients. For effective inhibition of the replicating virus, treatment must be promptly initiated at the onset of the infection.

Ribavirin (Virazole)

View full drug information

Ribavirin is an analogue of the nucleic acid guanosine. It inhibits viral replication through an unknown mechanism.

Class Summary

Bronchodilators act to decrease muscle tone in the small and large airways in the lungs, thereby increasing ventilation. Beta₂ -adrenergic and alpha-adrenergic agents are frequently administered (via inhalation) in an attempt to treat the bronchospasm observed in bronchiolitis.

Albuterol (AccuNeb, Proventil, ProAir HFA)

View full drug information

As a selective beta2-agonist, albuterol produces bronchial smooth muscle relaxation. Its efficacy in older children with reactive airway disease is well established, but its benefits in children with acute bronchiolitis are less well established. It is available in inhaled and oral preparations.

Epinephrine racemic

View full drug information

Racemic epinephrine consists of 1-1.125% of epinephrine base solution given by aerosol. It may be superior to beta2-adrenergic agents for treating RSV lower respiratory tract infection.

Class Summary

Specific immunoglobulin products with anti-RSV activity have been developed for the prophylaxis of high-risk patients against RSV infection.

Palivizumab (Synagis)

View full drug information

Palivizumab is a humanized monoclonal antibody directed against the F (fusion) protein of RSV. Administered monthly through the RSV season, it has been demonstrated to decrease the chances of RSV hospitalization in premature babies who are at increased risk for severe RSV-related illness.

Questions

Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 Oct 20. 282(15):1440-6. [QxMD MEDLINE Link].
Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J. 2007 Aug. 26(8):733-9. [QxMD MEDLINE Link].
Welliver RC. Bronchiolitis and infectious asthma. Feigin RD, Cherry JD, Demmler-Harrison G J, Kaplan SLeds. Textbook of Pediatric Infectious Diseases. 6th edition. Philadelphia, PA: Saunders Elsevier; 2009. 277-288.
Oray-Schrom P, Phoenix C, St Martin D, Amoateng-Adjepong Y. Sepsis workup in febrile infants 0-90 days of age with respiratory syncytial virus infection. Pediatr Emerg Care. 2003 Oct. 19(5):314-9. [QxMD MEDLINE Link].
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28. 352(17):1749-59. [QxMD MEDLINE Link].
Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade SW, et al. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States. Am J Perinatol. 2018 Jan. 35 (2):192-200. [QxMD MEDLINE Link].
Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, et al. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. Am J Perinatol. 2017 Jan. 34 (1):51-61. [QxMD MEDLINE Link].
Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infect Dis Ther. 2016 Sep. 5 (3):271-98. [QxMD MEDLINE Link].
Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003 Nov. 143(5 Suppl):S127-32. [QxMD MEDLINE Link].
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8. 289(2):179-86. [QxMD MEDLINE Link].
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5. 360(6):588-98. [QxMD MEDLINE Link].
Paes B, Mitchell I, Li A, Lanctôt KL. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis. 2012 May 1. [QxMD MEDLINE Link].
Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012 Jan. 21(1):53-60. [QxMD MEDLINE Link].
Kitsantas P, Nirmalraj L. Effects of Respiratory Syncytial Virus Infection in Infancy on Asthma and Respiratory Allergy in 6-Year-Old Children. South Med J. 2018 Nov. 111 (11):698-702. [QxMD MEDLINE Link].
Corneli HM, Zorc JJ, Mahajan P, Majahan P, Shaw KN, Holubkov R. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007 Jul 26. 357(4):331-9. [QxMD MEDLINE Link].
Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. J Pediatr. 1981 Jul. 99(1):100-3. [QxMD MEDLINE Link].
Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytialvirus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct. 143(4):532-40. [QxMD MEDLINE Link].
Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998 Sep. 102(3 Pt 1):531-7. [QxMD MEDLINE Link].
[Guideline] Committee on Infectious Diseases; American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases. 2003:523-528.
From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009 Dec. 124(6):1694-701. [QxMD MEDLINE Link].
Barclay, L. AAP: Palivizumab RSV Prophylaxis Guidelines Updated. Medscape Medical News. Available at http://www.medscape.com/viewarticle/828957. Accessed: August 4, 2014.
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug. 134 (2):415-20. [QxMD MEDLINE Link].
Rietveld E, Steyerberg EW, Polder JJ, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010 Jul. 95(7):493-8. [QxMD MEDLINE Link].
Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007 Jul. 151(1):34-42, 42.e1. [QxMD MEDLINE Link].
Yi H, Lanctôt KL, Bont L, Bloemers BL, Weijerman M, Broers C, et al. Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study. Pediatrics. 2014 May 5. [QxMD MEDLINE Link].
Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010 Jan. 125(1):e35-51. [QxMD MEDLINE Link].
Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. 1998 Jul. 11(3):430-9. [QxMD MEDLINE Link].
Belderbos ME, Houben ML, Wilbrink B, et al. Cord blood vitamin d deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011 Jun. 127(6):e1513-20. [QxMD MEDLINE Link].
Hall CB, Dougla RG, Geiman JM, Messner MK. Nosocomial respiratory syncytial virus infections. N Engl J Med. 1975. 293:1343-6. [QxMD MEDLINE Link].
Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000 Dec. 137(6):865-70. [QxMD MEDLINE Link].
Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015 Apr. 169 (4):341-8. [QxMD MEDLINE Link].
Harding A. Spreading Out Palivizumab Shots Improves RSV Protection. Reuters Health Information. Available at http://www.medscape.com/viewarticle/840348. February 25, 2015; Accessed: June 26, 2015.
Lavoie PM, Solimano A, Taylor R, Kwan E, Claydon J, Turvey SE, et al. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab. JAMA Pediatr. 2016 Feb. 170 (2):174-6. [QxMD MEDLINE Link].
Ambrose CS, Anderson EJ, Simoes EA, et al. Respiratory syncytial virus disease in preterm infants in the US born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014 Jun. 33(6):576-82. [QxMD MEDLINE Link]. [Full Text].
AstraZeneca. New study reveals significant burden of RSV disease among U.S. preterm infants born at 32-35 weeks. Medical News Today. June 5, 2014. [Full Text].
Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, et al. Novel Inflammatory Markers, Clinical Risk Factors, and Virus Type Associated with Severe Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2013 Jun 25. [QxMD MEDLINE Link].
Respiratory Syncytial Virus Infection (RSV): Trends and Surveillance. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/rsv/research/us-surveillance.html. June 26, 2018; Accessed: February 14, 2019.

Media Gallery

Respiratory syncytial virus infection season, United States, by region and Florida. Image courtesy of Centers for Disease Control and Prevention.
Electron micrograph of respiratory syncytial virus (RSV). RSV is most common cause of bronchiolitis and pneumonia in children younger than 1 year. Image courtesy of Centers for Disease Control and Prevention.

of 2

Author

Leonard R Krilov, MD Chief of Pediatric Infectious Diseases and International Adoption, Vice Chair, Department of Pediatrics, Winthrop University Hospital; Professor of Pediatrics, Stony Brook University School of Medicine

Leonard R Krilov, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Coauthor(s)

Asif Noor, MD Assistant Professor of Pediatric Infectious Diseases, NYU Long Island School of Medicine

Asif Noor, MD is a member of the following medical societies: American Academy of Pediatrics, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Ashir Kumar, MD, MB Professor Emeritus, Department of Pediatrics and Human Development, Michigan State University College of Human Medicine

Ashir Kumar, MD, MB is a member of the following medical societies: American Association of Physicians of Indian Origin and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Larry I Lutwick, MD Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Sections Respiratory Syncytial Virus Infection
Overview
Presentation
DDx
Workup
Treatment
Medication
Questions & Answers
Media Gallery
References

Respiratory Syncytial Virus Infection Medication

Medication Summary

Antiviral agents